Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen

Identifying breast cancer patients most

Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen

✍ Christopher M. Booth; Joseph L. Pater; Paul E. Goss 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB

Identifying Breast Cancer Patients Most Likely to Benefit From Aromatase Inhibitor Therapy After Adjuvant Tamoxifen W e are responding to the recently published study by Freedman and colleagues in which it is suggested that the benefits of adding an aromatase inhibitor after 5 years of adjuvant tamo